You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 19, 2024

PROPECIA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Propecia patents expire, and when can generic versions of Propecia launch?

Propecia is a drug marketed by Organon and is included in one NDA.

The generic ingredient in PROPECIA is finasteride. There are fourteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the finasteride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Propecia

A generic version of PROPECIA was approved as finasteride by DR REDDYS LABS INC on July 28th, 2006.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for PROPECIA?
  • What are the global sales for PROPECIA?
  • What is Average Wholesale Price for PROPECIA?
Drug patent expirations by year for PROPECIA
Drug Prices for PROPECIA

See drug prices for PROPECIA

Drug Sales Revenue Trends for PROPECIA

See drug sales revenues for PROPECIA

Recent Clinical Trials for PROPECIA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Follicle Pharma LtdPhase 1
Inventage Lab., Inc.Phase 1/Phase 2
Polichem S.A.Phase 3

See all PROPECIA clinical trials

Pharmacology for PROPECIA

US Patents and Regulatory Information for PROPECIA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon PROPECIA finasteride TABLET;ORAL 020788-001 Dec 19, 1997 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PROPECIA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Organon PROPECIA finasteride TABLET;ORAL 020788-001 Dec 19, 1997 ⤷  Sign Up ⤷  Sign Up
Organon PROPECIA finasteride TABLET;ORAL 020788-001 Dec 19, 1997 ⤷  Sign Up ⤷  Sign Up
Organon PROPECIA finasteride TABLET;ORAL 020788-001 Dec 19, 1997 ⤷  Sign Up ⤷  Sign Up
Organon PROPECIA finasteride TABLET;ORAL 020788-001 Dec 19, 1997 ⤷  Sign Up ⤷  Sign Up
Organon PROPECIA finasteride TABLET;ORAL 020788-001 Dec 19, 1997 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for PROPECIA

See the table below for patents covering PROPECIA around the world.

Country Patent Number Title Estimated Expiration
Argentina 225045 PROCEDIMIENTO PARA PREPARAR NUEVAS 17 BETA-N,N-DIETIL-CARBAMOTIL-4-METIL-4AZA-5ALFA-ANDROSTAN-3ONAS UTILES COMO INHIBIDORES DE 5ALFA-REDUCTASA ⤷  Sign Up
Bulgaria 62362 ⤷  Sign Up
Greece 3029554 ⤷  Sign Up
Poland 223577 ⤷  Sign Up
Norway 932155 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for PROPECIA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0155096 SPC/GB93/006 United Kingdom ⤷  Sign Up SPC/GB93/006:, EXPIRES: 20070526
0155096 93C0055 Belgium ⤷  Sign Up PRODUCT NAME: FINASTERIDUM; NAT. REG..: 922 IS 151 F 3 19930125; FIRST REG.: GB PL 0025/0279 19920527
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.